Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTSHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
DRTS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.32B
- EPS (TTM)
- -$1.04
- Dividend yield
- None
- 52-week range
- 3.43 – 15.79
- Day range
- 14.10 – 14.41
- Volume / Avg
- 466.26K / 568.24K
- Beta
- —
- Shares outstanding
- 92.48M
- Next earnings
- Nov 19, 2026
52-week range
DRTS stock today
On Oct 7, DRTS ended the session at $14.25, shedding $0.23 (1.59%), versus the S&P 500's 0.22% decline. Shares are 9.8% below their 52-week high of $15.79, set on Sep 17, 2026 and 315.5% above the 52-week low of $3.43, near the top of the past year's range. DRTS is up 187.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 245.0%.
Alpha Tau Medical has posted a net loss over the last twelve months (EPS of -$1.04), so its P/E ratio is not meaningful. Alpha Tau Medical's next earnings report is expected on Nov 19, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Alpha Tau Medical
Company profileAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Uzi Sofer
- Headquarters
- Jerusalem
- Employees
- 121
- Website
- alphatau.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$17.80+24.91%
- Strong buy 1
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 19, 2026
Alpha Tau Medical peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COAGHemab Therapeutics Holdings Inc. | 28.70 | +1.16% | $1.34B | vs DRTS |
| OMEROmeros Corporation | 18.75 | +1.30% | $1.36B | vs DRTS |
| ANABAnaptysBio Inc. | 45.65 | -4.68% | $1.36B | vs DRTS |
| KLRAKailera Therapeutics Inc. | 10.53 | -2.77% | $1.37B | vs DRTS |
| INBXInhibrx Biosciences Inc. | 93.36 | -0.05% | $1.37B | vs DRTS |
| NKTRNektar Therapeutics | 40.26 | +0.88% | $1.37B | vs DRTS |
| KARDKardigan Inc. | 13.83 | +2.52% | $1.29B | vs DRTS |
| AAPGAscentage Pharma Group International American Depository Shares | 14.94 | -7.15% | $1.40B | vs DRTS |
Indexes, lists and sector
Appears in lists
Alpha Tau Medical stock FAQ
What is Alpha Tau Medical's stock price today?
DRTS last traded at $14.25 as of Oct 7, 4:00 PM EDT, down 1.59% on the day. Prices are delayed at least 15 minutes.
When is Alpha Tau Medical's next earnings date?
Alpha Tau Medical is expected to report earnings on Thursday, November 19, 2026.
Who is Alpha Tau Medical's CEO?
Mr. Uzi Sofer is the chief executive officer of Alpha Tau Medical Ltd., which has about 121 employees.
What is the DRTS 52-week high?
The 52-week high for DRTS is $15.79 and the 52-week low is $3.43. The stock is currently 9.8% below its high.